- Home
- ATXS vs MEGI Comparison
ATXS vs MEGI Comparison
Compare ATXS & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATXS | MEGI |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 709.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATXS | MEGI |
|---|---|---|
| Price | $12.58 | $13.92 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | ★ 793.4K | 178.0K |
| Earning Date | 03-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.40% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $706,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.56 | $10.63 |
| 52 Week High | $13.29 | $14.89 |
Technical Indicators
Market Signals| Indicator | ATXS | MEGI |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 57.81 |
| Support Level | $12.24 | $13.76 |
| Resistance Level | $12.86 | $13.96 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 32.54 | 90.38 |
Price Performance
Historical ComparisonAbout ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.